Please enable JavaScript.
Coggle requires JavaScript to display documents.
Non-Alcoholic Fatty Liver Disease (NAFLD)/Metabolic Dysfunction-Associated…
Non-Alcoholic Fatty Liver Disease (NAFLD)/Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Epidimiology
Global Prevalence
Affects approximately 25% to 30% of the adult population worldwide. The progressive inflammatory subtype, non-alcoholic steatohepatitis (NASH / MASH), affects roughly 3% to 6% of adults.
Metabolic Comorbidities: Strongly linked to metabolic syndrome components:
Dyslipidemia & Hypertension: Present in >60% of patients.
Obesity: Found in 80% to 90% of adults with severe obesity (BMI ≥ 35).
Type 2 Diabetes Mellitus (T2DM): Prevalence of NAFLD/MASLD exceeds 65% to 70%.
Disparities & Ethnicity
Highest prevalence observed among Hispanic/Latino populations, attributed to a higher frequency of risk-associated genetic variants, followed by non-Hispanic White populations, with lower rates observed in non-Hispanic Black individuals.
Mortality
Cardiovascular disease (CVD) is the leading cause of death in patients with NAFLD/MASLD, followed by extrahepatic malignancies and liver-related complications (cirrhosis and hepatocellular carcinoma [HCC]).
Pathophysiology
The pathogenesis of NAFLD/MASLD is described by the "Multiple-Parallel Hit" Hypothesis, where concurrent metabolic, inflammatory, and genetic factors drive disease progression from simple steatosis to steatohepatitis and fibrosis.
Insulin Resistance & Lipotoxicity
Hyperinsulinemia and insulin resistance impair suppression of peripheral lipolysis, increasing free fatty acid (FFA) flux to the liver. Simultaneously, hepatic de novo lipogenesis (DNL) is upregulated.
Hepatocyte Injury & Inflammation
Excess FFAs exceed mitochondrial beta-oxidation capacity, generating reactive oxygen species (ROS), endoplasmic reticulum (ER) stress, and toxic lipid intermediates (diacylglycerols, ceramides). This "lipotoxicity" triggers hepatocyte ballooning, apoptosis, and recruitment of inflammatory macrophages releasing TNF-alpha and IL-6.
Fibrogenesis
Persistent inflammation activates hepatic stellate cells (HSCs), converting them into myofibroblast-like cells that deposit excess Type I and III collagen into the extracellular matrix, leading to progressive periperisinusoidal fibrosis and remodeling into cirrhosis.
Assessment, Diagnosis, Management and Evaluation
Most patients with early-stage NAFLD/MASLD are entirely asymptomatic, with the condition frequently identified incidentally via elevated transaminases or routine abdominal imaging.
Subjective Symptoms
Fatigue, right upper quadrant (RUQ) abdominal fullness or dull ache, malaise, daylight somnolence.
Physical Exam (Early/Moderate)
Hepatomegaly (smooth, tender liver edge), elevated Body Mass Index (BMI ≥ 25 or ≥ 23 in Asian populations), central/visceral adiposity (waist circumference >102 cm in men, >88 cm in women), acanthosis nigricans (sign of severe insulin resistance)
Physical Exam (Advanced Fibrosis/Cirrhosis)
Palmar erythema, spider angiomas, temporal wasting, muscle loss, jaundice, ascites, splenomegaly, peripheral lower extremity edema, asterixis, and caput medusae.
History Interview Questions
Alcohol Consumption Screening (Crucial Exclsion): "How many alcoholic drinks do you consume per week?" (Rule out alcoholic liver disease: threshold <20 g/day for women, <30 g/day for men. Use validated screening tools (AUDIT-C).
Medication & Supplement Review: "Are you taking medications associated with secondary hepatic steatosis (e.g., systemic corticosteroids, amiodarone, methotrexate, tamoxifen, valproic acid) or over-the-counter herbal supplements?"
Family History: "Is there any history of cirrhosis, liver cancer, early-stage cardiovascular disease, or severe metabolic disease in your immediate family?"
Diagnosis
Non-Invasive Diagnostic Testing & Risk Stratification
Exclude Secondary Causes & Alcohol Overconsumption
Calculate Baseline FIB-4 Score
FIB-4 < 1.30 (Low Risk)
Primary Care Management: with lifestyle modifications; re-assess in 2–3 years. (Cutoff < 2.0 for patients aged ≥ 65)
FIB-4 > 2.67 (Hiigh Risk)
FIB-4 1.30 - 2.67 (Intermediate Risk)
VCTE / FibroScan Testing or ELF Serum Panel
LSM < 8 kPa (Low Risk)
Primary Care Follow-Up Requires secondary non-invasive testing (e.g., Transient Elastography).
LSM >= 8 kPa (Moderate-High Risk)
Indicates high likelihood of advanced fibrosis (F ≥ 3). Direct referral to Gastroenterology/Hepatology.
Secondary Diagnostic Tests
Vibration-Controlled Transient Elastography (VCTE / FibroScan):
Liver Stiffness Measurement (LSM): Quantifies hepatic fibrosis (measured in kPa). LSM < 8 kPa rules out advanced fibrosis; LSM ≥ 12 kPa indicates high likelihood of advanced fibrosis/cirrhosis.
Controlled Attenuation Parameter (CAP): Quantifies hepatic steatosis (measured in dB/m).
Laboratory Biomarkers: Enhanced Liver Fibrosis (ELF) score, AST-to-Platelet Ratio Index (APRI), serum ferritin (rule out hemochromatosis and assess systemic inflammation), lipid panel, HbA1c, viral hepatitis panel (HBsAg, anti-HCV).
Imaging: Abdominal Ultrasound (detects steatosis >20–30%), MRI-Derived Proton Density Fat Fraction (MRI-PDFF; gold-standard imaging for quantifying fat fraction), MR Elastography (MRE).
Liver Biopsy: Gold standard for definitive diagnosis and staging of NASH/MASH and fibrosis, but reserved for diagnostic ambiguity, discordant non-invasive test results, or clinical trial eligibility.
APRN manages stable NAFLD/MASLD through a systematic workflow
Assess
• Measure BMI, waist circumference, blood pressure
• Review LFTs, HbA1c, lipid panel
• Calculate FIB-4 score and perform alcohol intake screen
Diagnose
• Confirm hepatic steatosis on imaging/biomarkers
• Exclude secondary causes (alcohol, medications, viral)
• Stratify fibrosis risk (Low / Indeterminate / High)
Manage
• Prescribe targeted lifestyle interventions (diet/exercise)
Physical Exercise Prescription: Minimum of 150– 300 minutes/week of moderate-intensity aerobic exercise (e.g., brisk walking, cycling) combined with 2–3 resistance training sessions weekly. Physical activity reduces hepatic fat independent of weight loss.
Targeted Weight Loss Goals
3–5% Weight Loss: Reduces hepatic steatosis.
7–10\% Weight Loss: Induces NASH/MASH resolution and promotes regression of hepatic fibrosis.
• Initiate cardiometabolic & liver-directed pharmacotherapy
Statin Therapy: Statins are safe and indicated in patients with NAFLD/MASLD for cardiovascular prevention. They do not increase the risk of severe liver injury and lower overall cardiovascular mortality.
• Manage dyslipidemia, T2DM, and hypertension
Glycemic Control: Target HbA1c < 7.0% using organ-protective agents (GLP-1 RAs, SGLT2 inhibitors).
Evaluate
• Monitor weight loss target (7-10%) and LFT normalization
• Repeat FIB-4 score every 12-24 months
• Evaluate treatment adherence and refer high-risk cases
Referral and Interprofessional Collaboration
APRN Primary Care Leader
Bariatric surgery BMI ≥ 35 with metabolic disease
• Patients with BMI ≥ 35 or BMI ≥ 30 with uncontrolled T2DM who have not achieved adequate weight loss through lifestyle and medical pharmacotherapy.
Cardiology ASCVD risk, Dyslipidemia
• Elevated 10-year Atherosclerotic Cardiovascular Disease (ASCVD) risk score, refractory hypertriglyceridemia, or established ischemic heart disease.
Endocrinology Refractory (Type-II DM, insulin)
• Poorly controlled Type 2 Diabetes (HbA1c > 8.5%) despite dual oral therapy.
• Complex insulin titration or candidacy for advanced incretin-based therapies.
Hepatology/GI High Fib-4 > 1.30, Cirrhosis, HCC
• HCC surveillance screening in cirrhotic patients (ultrasound +/-alpha-fetoprotein every 6 months).
• Diagnostic ambiguity requiring liver biopsy consideration.
• Clinical, laboratory, or imaging evidence of cirrhosis, portal hypertension, ascites, or hepatic encephalopathy.
• FIB-4 score > 2.67 (high risk for advanced fibrosis).
• FIB-4 score > 1.30 with indeterminate or elevated VCTE LSM (≥ 8 kPa)
Dietitian / RD (Medical Nutrition Therapy)
• Individualized Medical Nutrition Therapy (MNT) for sustainable weight loss, Mediterranean diet transition, and caloric deficit structure.
Patient, Family, Community Roles and Patient Education
Family Role: Participate in home meal planning, eliminate sugar-sweetened beverages from the household, and engage in shared physical activity.
Community Role: Advocate for accessible walking trails, community gardens, affordable fresh produce in food deserts, and structured group weight management programs.
Client Role: Actively monitor daily physical activity, track meal compositions, adhere to prescribed cardiometabolic medications, and avoid alcohol.
Patient Educational Materials & Tools
"Understanding Your Fatty Liver" Action Plan: A three-tiered visual guide categorizing actions into:
Yellow Zone (Warning): Weight gain, elevated HbA1c, high sugar intake- contact APRN for dietary counseling adjustment and pharmacotherapy review.
Red Zone (Urgent): Development of dark urine, jaundice, leg swelling, abdominal distension, or confusion -immediate clinical evaluation.
Green Zone (Optimal): Weight loss target achieved, daily Mediterranean diet adherence, regular exercise, normal LFTs.
Psychosocial, Cultural, Genetic, and Environmental Influences
Psychosocial Factors & Behavioral Health
Depression & Anxiety Screening: Utilize validated screening tools (PHQ-9 and GAD-7) routinely, as depression correlates with poor lifestyle adherence and higher rates of severe obesity.
Stigma & Body Image: Patients with NAFLD/MASLD frequently encounter weight bias and stigma, leading to delayed medical care and emotional distress.
Cultural Adaptation of Nutrition
Adapt dietary plans to align with cultural preferences (e.g., substituting traditional high-glycemic carbohydrates in Hispanic, Asian, or African American diets with high-fiber whole grains, legumes, and traditional vegetables without sacrificing cultural identity).
Genetic Influences & "Lean NAFLD"
Other Variants: Mutations in TM6SF2 and MBOAT7 also increase susceptibility.
Lean NAFLD/MASLD: Patients with a normal BMI (BMI < 25 or <23 in Asian populations) can develop steatohepatitis due to genetic susceptibility and visceral adiposity. They require identical screening and risk stratification.
PNPLA3 Gene Mutation (rs738409 C>G / I148M): The PNPLA3 variant impairs triacylglycerol hydrolysis in hepatocytes, leading to severe hepatic steatosis and higher fibrosis progression risk independent of body mass index.
Interrelated System Roles (Client, Family, Community)
Family Role: Participate in home meal planning, eliminate sugar-sweetened beverages from the household, and engage in shared physical activity.
Community Role: Advocate for accessible walking trails, community gardens, affordable fresh produce in food deserts, and structured group weight management programs.
Client Role: Actively monitor daily physical activity, track meal compositions, adhere to prescribed cardiometabolic medications, and avoid alcohol.
Integration of Information Technologies
Health Information Technology (HIT) Tools
Digital Weight & Physical Activity Tracking: Integration of mobile health (mHealth) applications and wearable fitness sensors to monitor physical activity, daily caloric intake, and weekly weight trends.
EHR-Integrated FIB-4 Automated Calculators: Clinical decision support tools embedded in electronic health records that automatically calculate FIB-4 scores from lab data and alert APRNs to high-risk scores (>1.30 or >2.67).
Medical Resources and APRN Scope
APRN-Primary Care Management
Autonomous Clinical Assessment and Diagnostics:
APRNs obtain comprehensive histories assessing alcohol consumption, medication use, metabolic risk factors, and family history of liver disease. Order and interpret liver function tests, complete blood counts, metabolic panels, hepatitis screening when indicated, and noninvasive fibrosis assessments to identify patients at risk for advanced liver disease.
Risk Stratification and Fibrosis Assessment: APRNs calculate FIB-4 using patient age, aspartate aminotransferase (AST), alanine aminotransferase (ALT), and platelet count. Patients with FIB-4 below 1.3 generally remain in primary care with periodic reassessment, while results of 1.3 or greater typically warrant secondary evaluation with transient elastography or Enhanced Liver Fibrosis (ELF) testing. A different cutoff applies to patients older than 65.
Pharmacological Management: APRNs manage associated metabolic conditions through evidence-based prescribing, including statins for cardiovascular risk reduction and glucagon-like peptide-1 receptor agonists when indicated for diabetes or obesity. Disease-specific pharmacotherapy, including resmetirom or semaglutide where approved and appropriate, requires assessment of fibrosis stage, eligibility, contraindications, and monitoring requirements.
Long-Term Monitoring and Disease Prevention: APRNs monitor liver enzymes, metabolic parameters, weight, medication response, and fibrosis risk. Patients with type 2 diabetes or multiple metabolic risk factors may require FIB-4 reassessment every 1–2 years, while lower-risk patients may be reassessed every 2–3 years.
Clinical Practice Resources
AASLD practice guidance provides evidence-based recommendations for identifying patients at risk for MASLD< evaluating metabolic comorbidities, and assessing liver fibrosis.
EASL-EASD-EASO clinical practice guidelines: establish standardized approaches to diagnosing and managing MASLD, emphasizing cardiovascular risk reduction, lifestyle modifications, and early identification of advanced fibrosis.
UpToDate clinical decision support: Provided APRNs with current evidence regarding diagnostic evaluation, differential diagnoses, pharmacologic treatment options, and long-term monitoring of MASLD. Supports individualized management of obesity, type 2 diabetes, dyslipidemia, and hypertension.
Care Coordination and Referral Responsibilities
Specialty Referral and Advanced Disease Management: APRNs initiate hepatology referrals for FIB-4 greater than 2.67, persistent liver enzyme elevations lasting more than six months, suspected advanced fibrosis, or evidence of cirrhosis. Early referral supports additional diagnostic evaluation, surveillance for complications, and consideration of specialized treatment.
Interprofessional Collaboration and Medication Optimization: APRNs collaborate with hepatologists, endocrinologists, registered dietitians, and clinical pharmacists to address metabolic comorbidities, optimize medication regimens, minimize unnecessary polypharmacy, and improve long-term treatment adherence.
Patient-Centered Education and Shared Decision-Making: APRNs provide individualized education regarding Mediterranean-style dietary patterns, physical activity, weight reduction, alcohol avoidance, and cardiovascular risk reduction. Treatment goals are developed collaboratively while considering financial barriers, cultural preferences, health literacy, and access to care.